Standard collection of Aristotle's six works on logic
POPULARITY
56 episodes with Organon
48 episodes with Organon
8 episodes with Organon
13 episodes with Organon
6 episodes with Organon
3 episodes with Organon
3 episodes with Organon
3 episodes with Organon
2 episodes with Organon
In Episode 117 of Strange, Rare, and Peculiar, Denise Straiges and Alastair Gray answer listener questions about what happens when homeopathic principles meet real-life complexity.They take on polypharmacy in emergency situations, veterinary homeopathy with traumatized rescue dogs, and the harder question many people quietly carry: What if I've tried homeopathy—and nothing changed?Get your Organon out for this one. Denise and Alastair discuss Aphorisms 148 and 260, exploring what Hahnemann had to say about the labor of true homeopathic practice, obstacles to cure, and why homeopathy asks for more than shortcuts.In this episode:When, if ever, more than one remedy makes senseHomeopathy for animals in acute stressWhy “nothing happened” may not always mean nothing happenedObstacles to cure and case managementHahnemann, roasted pigeons, and the work homeopathy requiresStrange, Rare & Peculiar is a weekly podcast with Denise Straiges and Alastair Gray of the Institute for the Advancement of Homeopathy and the Academy of Homeopathy Education.This season, we're focusing on truth — what it means to Aude Sapere (“dare to know”) in homeopathy today. From Hahnemann's original insights to the realities of modern practice, research, and education, Denise and Alastair bring over 50 years of experience to conversations that challenge assumptions and invite curiosity.
India's largest drugmaker, Sun Pharma, has announced the acquisition of US-based Organon in a landmark $11.75 billion all-cash deal, the biggest overseas purchase by an Indian company since Tata-Corus in 2007. The move effectively doubles Sun Pharma's size, vaulting it into the top 25 global pharmaceutical companies with combined revenues of $12.4 billion. Host Anirban Chowdhury talks to ET's pharma expert Vikas Dandekar and associate editor Arijit Barman about why this deal gives Sun Pharma an instant foothold in biosimilars, a dominant position in global women's health, and a portfolio of established brands across 150 countries. With $2.5 billion in combined pre-financing free cash flows, the company looks well-positioned to tackle Organon's inherited debt burden.See omnystudio.com/listener for privacy information.
On Episode 859 of The Core Report, financial journalist Govindraj Ethiraj talks to Atanu Mukherjee, CEO at Dastur Energy as well as Thomas V Abraham, Research Analyst at Mirae Asset Sharekhan.SHOW NOTES(00:00) Stories of the Day(01:19) Markets slide as oil prices rise again(04:12) Nestle bucks sluggishness in FMCG, stock hits fresh high(04:44) Indigo, Air India have told the Government they are under extreme stress and on the verge of "stopping operations" because of high prices(06:43) UAE has quit OPEC(07:38) Decoding the medium to long term outlook for oil and gas production in India(23:39) Sun Pharma's $12 billion acquisition of Organon will double its size, a deep dive(30:42) New data centres take off in India but concern about them on OpenAI brassCheck out our Live Earnings tracker: https://earnings.thecore.in/For more of our coverage check out thecore.inSubscribe to our NewsletterFollow us on:Twitter |Instagram |Facebook |Linkedin |Youtube
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a fascinating array of industry shifts and scientific breakthroughs that are shaping the future of medicine and patient care. Sun Pharma's acquisition of Organon for $11.75 billion is making waves as it marks a significant expansion for the Indian pharmaceutical giant into international markets. This deal not only amplifies Sun Pharma's footprint but also integrates Organon's strong focus on women's health and biosimilars into its portfolio. It's a strategic move that underscores the increasing trend of cross-border mergers as companies seek to diversify and enhance their global presence. As the largest-ever overseas acquisition by an Indian firm, this transaction is emblematic of the growing importance of global consolidation in the pharma industry. Meanwhile, Astellas Pharma faces a mixed fiscal outlook with its prostate cancer drug Xtandi. While Xtandi experienced a modest sales increase in 2025, a projected decline for 2026 has prompted Astellas to pivot towards developing new medicines. This highlights the critical dependence on innovation within the industry to sustain growth, especially as competition intensifies. In the realm of ATTR amyloidosis treatments, Pfizer has reached a settlement with two generic manufacturers over its drug Vyndamax. This resolution is crucial in stabilizing the market amidst rising generic competition, which can significantly influence pricing and market dynamics. Such settlements are an integral part of maintaining competitive positioning in crowded therapeutic spaces. Ligand Pharmaceuticals' strategic purchase of XOMA for $739 million signals a broader trend of consolidation among biotech royalty aggregators. This acquisition aligns with Ligand's strategy to augment its portfolio through mergers and acquisitions—a recurring theme as biotech companies strive to streamline operations and expand their competitive edge. The competition within the oral GLP-1 market is intensifying, particularly with Eli Lilly's delayed launch of Foundayo inadvertently benefiting Novo Nordisk's market position. This rivalry underscores the fierce race to dominate the lucrative obesity management sector, highlighting how pivotal timing can be in gaining market share. The FDA's recent allocation of national priority vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics marks a significant regulatory shift towards embracing psychedelic therapies. These vouchers could expedite development timelines, thereby accelerating patient access to novel treatments that have traditionally been underexplored. Thermo Fisher Scientific's robust start to 2026 showcases how strategic acquisitions like that of Clario can drive growth. This reflects broader industry trends where biopharma companies leverage technological advancements to enhance capabilities in clinical trial support and data management. In gene editing news, Intellia Therapeutics is advancing towards FDA approval for its in vivo CRISPR therapy following successful Phase 3 trials. This progress heralds a new era for gene editing technologies in treating genetic disorders, underscoring their potential to revolutionize therapeutic approaches. Eli Lilly continues its aggressive acquisition strategy by purchasing Ajax Therapeutics for $2.3 billion. This acquisition focuses on next-generation JAK inhibitors for myelofibrosis, aligning with Lilly's broader goal to diversify its pipeline and maintain its leadership in innovative therapeutics. Recent studies have also shed light on how an endoscopic procedure used in Europe can aid patients on Eli Lilly's tirzepatide in maintaining weight loss post-treatment. This finding could significantly impact long-term obesity management strategies, offering new insights into sustainaSupport the show
The government is preparing a Rs 2.5 lakh crore credit guarantee scheme to support sectors such as aviation and MSMEs hit by the West Asian war. Airlines have warned of severe stress as fuel costs rise, while the UAE's exit from OPEC and OPEC+ could reshape global energy markets. Despite this uncertainty, EV demand remains robust, with electric car sales jumping 47% and two-wheeler registrations rising 28% in April. Sun Pharma, after its record Organon acquisition, plans to seek RBI approval for foreign remittance exemptions tied to corporate guarantees. Markets regulator Sebi is also considering a uniform framework for options strike prices to improve trading efficiency. Meanwhile, banks are cutting credit card perks, with airport lounge access among the first benefits to be capped.
India Inc is in the middle of a major transformation. Sun Pharma has acquired US-based Organon in the biggest-ever overseas deal by an Indian drugmaker. Tata Trusts are set to hold a crucial meeting on May 8, where issues such as a fresh term for N Chandrasekaran, the possible listing of Tata Sons, and governance matters may come up for discussion. Despite the West Asia war, early fourth-quarter earnings have surprised positively, with revenue growth hitting a three-year high and profits reaching a five-quarter peak. In capital markets, Acko is preparing for an IPO at a valuation of $2-2.5 billion. At the same time, AI-led disruption is reshaping IT and banking, driving stronger deal wins but also leaner hiring. Also inside: the surge in instant home services and how consumers are taking to them.
US equity futures are slightly higher, Asian markets are mixed, while European equities are lower. Risk sentiment remains cautious amid ongoing volatility around US-Iran developments, with uncertainty over negotiations and continued tensions in the Strait of Hormuz supporting oil prices and weighing on equities. Despite the geopolitical backdrop, markets are also digesting mixed signals from earnings and positioning after the recent rally, alongside evidence of a still-resilient macro environment highlighted by stronger PMI data, even as concerns persist around market breadth and potential near-term volatility.Companies mentioned: Nike, Spirit Airlines, Organon & Co., Sun Pharmaceutical Industries
Podcasting got a seat at the grown-up’s table at South by SouthWest for the first time, smack in middle of Women's History Month. So Insider Interviews captured content from three women also making strides in media, during Podcast Movement Evolutions. I spoke with these media powerhouses at The Podcast Academy / Sounds Profitable co-sponsored booth to talk about building: businesses, communities, the future of media itself…and building up women everywhere. Learn from: the co-founder of a startup modernizing how print and out-of-home are bought and sold, a global communications CEO who has built her career on making messaging move people, and one of the new forces behind podcasting's growing presence itself. Mach on Modernizing “Premium” Media for a New Era Beth Mach, Co-Founder & COO of Spacely Media, introduces the first transactional marketplace for premium media — giving print, out-of-home, and venue advertising the digital infrastructure it’s never had. “Buying in those channels today still looks like it did 20 years ago — lots of PDFs, lots of phone calls. Spacely closes that gap.” Their platform replaces friction with functionality, and dashboards instead of PDFs. Like Neil Vogel, in my recent episode with the People, Inc. CEO, Mach is bullish on magazines and makes the case for why brands are coming back to these channels. She also explains why credibility wins the room when you’re raising money. It shouldn’t be different as a female founder. But… “Every founder meets skepticism. When you are female, it adds another layer — especially when the room has historically looked a little different.” — Beth Mach Lund on Messaging to and for Humans Wendy Lund, Global CEO of Allison Worldwide and returning Insider Interviews guest (exactly one year later!), reflects on her path from women's health advocacy to leading a global agency — and what she's building now. Her path ran from a master’s in women’s history to nonprofit marketing, to running a global agency. With her move to Global CEO of Allison Worldwide and Vice Chair of health at parent company Stagwell, Wendy described her enthusiasm for Allison's strengths, across campaigns, media/influencer, and experiential. She reinforces the importance of listening, purpose-driven work, and addressing ongoing inequities in women's health and mental health. “My favorite value has always been belonging. Do your customers feel like they’re part of something? To me, that is so sticky.” Her advice for building brand love in a fragmented media world is deceptively simple: be real, and build belonging. She's also clear-eyed about the disconnect between how much we talk about innovation — and how much attention women's health actually gets: “AI is on the tip of everybody's tongue — but at the end of the day, it's also steeped in emotion. And we're 51% of the population. That means we should get 51% of the attention.” — Wendy Lund DeMellier Sounds Like an Inspiration Molly DeMellier, Head of Communications at Sounds Profitable, gives an insider's scoop on the organization helping shape podcasting's growing presence at SXSW and beyond. She points to the combined strengths of the co-founders: Bryan Barletta's (“terrifying”) encyclopedic industry brain and Tom Webster's research engine, along with her own expanding role shaping panel strategy, supporting retainer clients, and helping partners amplify their stories. Molly describes Sounds Profitable place in podcasting as building community and connection through events, networking, research, and partner support, emphasizing that “Podcasting is really taking off and it’s the people that power it.” But, noting the industry's representation gap, takes her role seriously when working on events like Podcast Movement, pondering “who do I put on stage that’s going to inspire that next person” to know they can see themselves podcasting. And she closes with something that sticks: her belief that women shouldn’t have to choose between a career and a family — and why she’s determined to make sure the next generation sees women in power. “A big fear I have is that women will leave professions not by choice, but by force. And my biggest fear is what about the children who see their mom who didn’t have a choice?” — Molly DeMellier This is Episode 50 in Season 2. I think it sounds like a milestone worth celebrating. Key Moments & Time Codes 00:00 — How Podcast Movement Evolutions made its first-ever appearance at SXSW 00:53 — Beth Mach explains why Spacely calls it premium media — and why that reframe matters for the industry 04:50 — Beth explains how buying a print ad in 2025 still works the way it did 20 years ago — and how Spacely is finally changing that 09:40 — Why print titles that shut down years ago are quietly relaunching — and what that signals for brands 14:55 — On fundraising as a female founder: the extra layer of skepticism, and how clarity of purpose cuts through it 16:30 — Wendy Lund returns one year later as Global CEO of Allison Worldwide — what changed, and why she missed agency life 22:21 — What Wendy learned going in-house at Organon: the difference between talking at women and actually listening to them 23:16 — Women’s health today: the innovations gaining ground and the conditions still being undertreated 27:35 — How Sounds Profitable brought the podcast industry to SXSW — and why community-building is at the core of everything they do 30:57 — What Sounds Profitable partners get: industry counsel, audience research expertise, and Molly’s evangelism that helps all boats rise! 34:59 — Closing thought as a woman in business: rising childcare costs are pushing women out of the workforce not by choice, but by force. Connect with E.B. Moss and Insider Interviews: With Media & Marketing Experts LinkedIn: https://www.linkedin.com/in/mossappeal Instagram: https://www.instagram.com/insiderinterviews Facebook: https://www.facebook.com/InsiderInterviewsPodcast/ Threads: https://www.threads.net/@insiderinterviews If you enjoyed this episode, follow Insider Interviews, share with another smart business leader, and leave a comment on @Apple or @Spotify… or a tip in my jar!: https://buymeacoffee.com/mossappeal!
Hear leading dermatologist Dr. E. James Song and patient advocate Ana Rinck share their perspectives on the use of biosimilars to manage psoriasis and psoriatic arthritis. The use of biosimilars is growing with 24 currently on the market and more on the way for the treatment of psoriasis and psoriatic arthritis. What does this mean for you? Find out as we explore the use of biosimilars, the impact of interchangeability, what it's like switching to a biosimilar, and what questions to ask your health care provider with leading dermatologist and NPF Medical Board member Dr. E. James Song, Director of Clinical Research at Frontier Dermatology Partners, and patient advocate Ana Rinck who currently uses a biosimilar to treat her psoriasis and psoriatic arthritis. The intent of this episode is to offer an update on the use of biosimilars and to hear the experience of those who have used biosimilars to manage psoriatic disease. This episode is sponsored by Organon. Timestamps: (0:00) Intro to Psoriasis Uncovered and guest welcome to dermatologist Dr. E. James Song, Director of Clinical Research and Co-Chief Medical Officer, Frontier Dermatology, and patient advocate Ana Rinck, who presents her experience with using a biosimilar to treat psoriasis and psoriatic arthritis. (0:58) Definition of what is a biosimilar in comparison to a biologic which is also referred to as the original bio-originator or reference product. (3:10) What biosimilars are available and how they are used. (4:35) The term interchangeable and what it means for use of a biosimilar. (5:46) Ana's diagnosis to treatment options starting with use of topicals to ultimately use of a biosimilar. (7:57) Treatment discussion and choices when faced with diminishing effectiveness within a class of medications. Should a biosimilar be considered as an option? (9:50) Questions to consider when there's a change in treatment. (10:57) FDA announcement to simplify the development process for biosimilars and what that means for the future use of biosimilars. (13:55) What to consider when thinking of a biosimilar as a treatment option and where to find help when needed. (14:53) The hope and equity of access that biosimilars represent is here for the appropriate individual. Key Takeaways: · A biosimilar is an FDA-approved biologic product that behaves and functions like a brand biologic treatment which is also called the reference product or bio-originator. There are no clinically meaningful differences between biosimilars and their reference product. · The FDA has approved several biosimilars for the treatment of psoriasis and psoriatic arthritis. Some have been identified as interchangeable which means a biosimilar could be substituted for a reference product without a health care provider's approval pending state legislative rules. · Don't be afraid to ask questions or access resources to assist with preparing for a medication change should that change be initiated either by yourself, your healthcare provider, or your health insurance company. Guest Bios: E. James Song, M.D. is a nationally recognized dermatologist and clinical researcher who is also a Clinical Instructor at the University of Washington. Dr Song is recognized as a key opinion leader in treating psoriasis and atopic dermatitis. He is actively involved in the development of new therapies for dermatologic disease and has firsthand experience with treatments before they come to market. Dr. Song has been published extensively in peer review journals and regularly participates in meetings both as a lecturer and attendee. He is also a Medical Board member of the National Psoriasis Foundation. He believes that the best health outcomes come from shared decision making between the patient and physician. Dr. Song strives to help patients understand not only their condition, but all their treatment options. Ana Rinck is a patient advocate and volunteer for the National Psoriasis Foundation. She developed psoriasis in 2009 following symptoms she noticed for a few years which proved to be challenging to diagnose. She managed for many years on topicals and intralesional injections. In 2018 she was diagnosed with psoriatic arthritis and started use of a biologic realizing she needed to protect her joints from further damage. She now uses a biosimilar to manage her psoriatic disease. Ana owns her own private consulting business and is an Operations and Project Manager. Resources: -Learn more about biosimilars, interchangeability, and state substitution rules. -Armstrong A, Callis Duffin K, Feldman S, Glick B, Kalb R, Reddy S, Schwartzman S, Yamauchi P, Calabrese C, Cordoro K, Desai S, Gladman D, Han G, Hawkes JE, Hsu S, Kircik L, Koo J, Kreuger GG, Lebwohl M, Leonardi C, Lewitt GM, Liao W, Liu C, Markenson J, Merola JF, Orbai A, Prussick R, Richardson V, Soung J, Van Voorhees AS, Wallace E, Weinberg J, Wine Lee L, Harris J, Koons S, Howard L. Position Statement on the Use of Biosimilars for Psoriasis and Psoriatic Arthritis. National Psoriasis Foundation Medical Board. 2023. -If you need help finding a dermatologist near you contact the NPF's Patient Navigation Center for assistance.
Dissimilar diseases cannot cure you, but instead will overpower the original dis-ease forcing the original set of symptoms to be dormant until the new disease is created by the allopathic medicine or drug. The original disease returns and the body now has more than one disease – the original one as well as the effects and side effects of the medication as seen in the new set of problems and new organs impacted by the ‘effect, side or otherwise' of the allopathic drug. Homeopathy works by creating a remedy that makes the same set of symptoms that the patients experience when tested, and then when taken the similar disease helps the body recognize the symptoms it is experiences, like a mirror held up and reflecting a similar picture as seen in the symptomology of the patient. We look at aphorisms 34 to 40 of the Organon of the Medical Art by Samuel Hahnemann, MD. All views presented are based on credible sources, but they are explained through the individual's viewpoint. Doing your own research while integrating new information is always important when forming your own viewpoint. Please feel free to contact me and share ideas on any of the topics on this podcast. I would love to hear from you at hownatureheals@gmail.com. You can also find me as a provider of natural medicine on the new platform: materiaplus.com where you can open an account and favourite me. Materia+ is a new marketplace for natural medicine and is in its beta phase of development. The information in this podcast is not meant to address individual health needs, it is general in nature and should not be used as medical information for your health unless used in combination with your health practitioner.
Mastering the Message: The Recruiter's Playbook Communication is where the candidate experience lives or dies. Is your messaging helping you close hires, or is it creating bottlenecks? Join us as we break down the Best Practices for Messaging Your Candidates. We'll tap into the knowledge of two experienced leaders including Kerry Noone, who runs Employer Brand at Ford Motor Company and Geoff Webb who runs Talent Discovery and Engagement at Canadian based Organon. Expect to walk away with: A timeline for perfect follow-ups. Communication etiquette for the modern age. Strategies to go beyond the ‘Thank You For Apply' email Who should attend: Talent Acquisition Leaders, HR Directors, Recruiters... Learn more about your ad choices. Visit megaphone.fm/adchoices
Implanon (etonogestrel implant) first received FDA approval in 2006, followed by the improved, radiopaque version, Nexplanon, approved by the FDA in 2010, which is now the only contraceptive implant available in the U.S. It was originally FDA approved for a 3-year use duration, although peer reviewed clinical data had demonstrated efficacy through year 5. Now, as of January 2026, the FDA has formally agreed to extend the label for 5-year use. In this episode, we will review the clinical data that prompted the FDA's decision, based on a multicenter, single-arm, open-label study evaluating contraceptive efficacy and safety during years 4 and 5 of implant use.1. https://www.contemporaryobgyn.net/view/fda-approves-5-year-use-for-etonogestrel-implant-68-mg-contraceptive2. Organon announces US Food and Drug Administration approval of supplemental new drug application extending duration of use of NEXPLANON (etonogestrel implant) 68 mg Radiopaque. Organon. Press release. January 16, 2026. Accessed January 19, 2026. https://www.organon.com/news/organon-announces-us-food-and-drug-administration-approval-of-supplemental-new-drug-application-extending-duration-of-use-of-nexplanon-etonogestrel-implant-68-mg-radiopaque/3. Ali M, Akin A, Bahamondes L, et al. Extended Use Up to 5 Years of the Etonogestrel-Releasing Subdermal Contraceptive Implant: Comparison to Levonorgestrel-Releasing Subdermal Implant. Human Reproduction. 2016. 4. McNicholas C, Swor E, Wan L, Peipert JF. Prolonged Use of the Etonogestrel Implant and Levonorgestrel Intrauterine Device: 2 Years Beyond Food and Drug Administration-Approved Duration. American Journal of Obstetrics and Gynecology. 2017. 5. McNicholas C, Maddipati R, Zhao Q, Swor E, Peipert JF. Use of the Etonogestrel Implant and Levonorgestrel Intrauterine Device Beyond the U.S. Food and Drug Administration-Approved Duration. Obstetrics and Gynecology. 2015.
In this special episode, Jen McIver and Diana Flanders take you behind the scenes of ELM Amplify 2025, which took place in Orlando in November 2025.Through rapid-fire, podcast-style conversations recorded on-site, Jen captures candid perspectives from legal ops managers, litigation leaders, and technology specialists representing Citizens Bank, Popular Bank, Westfield Insurance, Santander, Marsh McLennan, M&T Bank, and Organon. Together, they explore why fostering connection and candid knowledge-sharing is essential for driving innovation and shaping the future of legal operations.
‘Je voelt een aanval aankomen, maar wil het liefst gewoon doorgaan. Ik voel misselijkheid, gevoeligheid voor licht, het voelt alsof ik de wereld minder goed kan waarnemen, geluid is moeilijk, net als zinnen maken, praten en luisteren. Vaak lukt het mij nog wel om iets te produceren, maar opslaan wat jij tegen mij zegt dat lukt niet.'‘Het is moeilijk om je grenzen te bewaken. Je gaat er gauw overheen. Terwijl je eigenlijk moet zeggen: ‘ik ga naar huis.' En dan is het heel fijn als iemand tegen je zegt: ‘het is klaar. Het is tijd om naar huis gaan.'' ‘Ik denk dat we steeds meer inzien dat als we elkaar leren begrijpen en helpen we een veilige werksfeer creëren die uiteindelijk het werk dat je doet alleen maar beter kan maken.'Zoë liep met haar zus Loren de Nijmeegse vierdaagse om geld op te halen voor migraineonderzoek. Vier keer veertig kilometer omdat ze zelf als van jongs af aan last heeft van migraineaanvallen en hoopt dat er meer over bekend wordt. We vroegen of Zoë haar verhaal ook in de podcast wilde delen. Annemiek reisde naar Nijmegen en Loren sloot bij het gesprek aan. In de vorige aflevering (link) vertelde Zoë haar verhaal. Het gesprek dat Zoë, Loren en Annemiek na de opname voerden was zo treffend, dat Annemiek besloot om datzelfde gesprek ook voor de microfoon te voeren. Vandaar deze bonusaflevering! Wat is de impact van migraine op het dagelijks leven? Waar houdt Zoë rekening mee en hoe ervaart ze dat? En Voor mensen zoals Zoë en andere migrainepatiënten halen we geld op, zodat we nog beter onderzoek kunnen doen en migraine beter te voorspellen, voorkomen en behandelen. Lees meer over deze actie en doneer via deze link: ‘Inzicht kan helpen migraine te voorkomen' - Leids Universiteits Fonds.Het boek ‘Koppijn' van Gisela is uit! Je kunt het bestellen via lokale boekwinkels of via bol.comHeb je een vraag voor Gisela die we kunnen bespreken in de vragenrubriek? Laat het ons weten via Instagram, LinkedIn of e-mail. De Hoofdpijn podcast is een podcast van het Leidse Hoofdpijn Centrum. Aan het woord: Zoë en Loren Posthumus.Presentatie en inhoudelijke montage: Annemiek Lely.Eindmontage en mixage: popuppodcast.studio.Kijk voor meer informatie op www.hoofdpijnonderzoek.nl Het vierde seizoen van de Hoofdpijn podcast wordt mede mogelijk gemaakt door: Pfizer, Organon, Abbvie & Teva.
Dr. Ralf Jeutter discusses the foundational principles of Hahnemannian homeopathy. He emphasizes the importance of observing patients' unique experiences and symptoms, rather than categorizing diseases or personalities, highlighting Hahnemann's focus on phenomenology. Dr. Jeutter also explores common misconceptions in interpreting the Organon, particularly around mental and emotional symptoms, and stresses that remedies should be understood through careful study of provings and original texts. He cautions against oversimplifying remedies into psychological types, which can obscure the depth of each patient's experience. Throughout the conversation, he encourages a return to the core principles of homeopathy, combining attentive clinical observation with a thorough understanding of the remedies. Episode Highlights: 03:56 - Ralf's Journey into Homeopathy 09:45 - Accessing German Texts and the Organon 11:17 - Misconceptions in Interpreting the Organon 18:00 - What are we supposed to do in a homeopathic consultation 19:33 - Understanding the Altered State in Homeopathy 24:06 - Differences Between Hahnemannian and Kentian Homeopathy 28:59 - The Role of Mental Symptoms 30:17 - The Balance Between Psychological and Physical Symptoms 33:34 - What Truly Never Changed in Hahnemann's Homeopathy 41:43 - A Radical Shift in How We Understand Disease 49:57 - Re-examining the Syphilis Model 57:12 - When Everything Is Called Homeopathy 01:02:59 - Why Studying Hahnemann Still Matters 01:08:22 - Where Did Succussion Really Come From About my Guests: Dr. Ralf Jeutter has been involved in homeopathy for over 20 years and is an international teacher and practitioner. He qualified in homeopathy in 2000 from the North-West College of Homeopathy in the UK and continued his medical and homeopathic training at the Institute of Clinical Research in Bombay and Pune, India. He is medically trained in Podiatric Medicine and holds a Ph.D. in Literature and Philosophy. Dr. Jeutter is a former Director of the Society of Homeopaths, the largest homeopathic membership organisation in the UK. Dr. Jeutter is Head of Academic Affairs and Head of Philosophy at the Centre for Homeopathic Education (CHE) in New York and teaches homeopathy internationally, including in London, Budapest, and New York. For over 10 years, he has been involved in the Materia Medica Pura Project initiated and led by Dr. André Saine. His professional focus is on Hahnemannian homeopathy, comparative materia medica, repertory work, and a solid understanding of the foundations and philosophy of Hahnemann and his followers. To learn more about his masterclass on male health issues https://www.cheonline.co.uk/male-health-issues To learn more of his provings https://hpathy.com/ If you would like to support the Homeopathy Hangout Podcast, please consider making a donation by visiting www.EugenieKruger.com and click the DONATE button at the top of the site. Every donation about $10 will receive a shout-out on a future episode. Join my Homeopathy Hangout Podcast Facebook community here: https://www.facebook.com/groups/HelloHomies Follow me on Instagram https://www.instagram.com/eugeniekrugerhomeopathy/ Here is the link to my free 30-minute Homeopathy@Home online course: https://www.youtube.com/watch?v=vqBUpxO4pZQ&t=438s Upon completion of the course - and if you live in Australia - you can join my Facebook group for free acute advice (you'll need to answer a couple of questions about the course upon request to join): www.facebook.com/groups/eughom
Medsider Radio: Learn from Medical Device and Medtech Thought Leaders
In this episode of Medsider Radio, we sat down with Colby Holtshouse, President and CEO of May Health.May Health is developing a minimally invasive ovarian ablation therapy designed to restore ovulation in women with polycystic ovary syndrome (PCOS) and PCOS-related infertility.Before May Health, Colby served as Global Medtech Commercial Lead at Organon, overseeing the worldwide launch of the Jada System following Organon's acquisition of Alydia Health, where she held roles including COO, Interim CEO, and VP of Marketing. She has also held leadership positions at Pelvalon, AccessClosure, Medtronic, and Guidant.In this discussion, Colby shares why early clinical evidence should be built in focused layers rather than oversized, all-at-once trials. She explains how a small, deliberate early launch can reveal the workflow nuances and real-world expectations no study ever captures. And she outlines why founders should define the raise first — and how clarity, preparation, and a deep understanding of strategic partners can dramatically accelerate the fundraising process.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Colby Holtshouse.
In this episode we discuss:PosologyFibonacci homochordsCreative interpretations of the OrganonResearch & case management over timeHomeopathy's historical recordWhere homeopathy lives and breathes.Welcome to Strange, Rare & Peculiar — a weekly podcast with Denise Straiges and Alastair Gray of the Institute for the Advancement of Homeopathy and the Academy of Homeopathy Education.This season, we're focusing on truth — what it means to Aude Sapere (“dare to know”) in homeopathy today. From Hahnemann's original insights to the realities of modern practice, research, and education, Denise and Alastair bring over 50 years of experience to conversations that challenge assumptions and invite curiosity.
Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a myriad of pivotal changes and advancements that have been shaping our industry.The competitive nature of acquisitions within the biopharma sector has been exemplified by recent strategic buyouts. Lundbeck's decision to outbid Alkermes for Avadel Pharmaceuticals highlights how companies are leveraging acquisitions to expand their capabilities and portfolios. Similarly, Pfizer's finalized acquisition of Metsera after a fierce bidding war with Novo Nordisk underscores the importance of securing valuable assets to strengthen positioning in critical therapeutic areas, such as obesity treatment, where demand continues to rise.Regulatory milestones remain at the heart of industry progress. Organon and Henlius's Poherdy recently received FDA approval as a biosimilar to Roche's Perjeta, offering a new treatment avenue for HER2-positive breast cancer patients. This approval is noteworthy as biosimilars play an essential role in oncology by providing similar efficacy to original biologics but at reduced costs, thereby enhancing healthcare affordability and accessibility. In Europe, the EMA's Committee for Medicinal Products for Human Use has endorsed several innovative drugs, including Otsuka's Dawnzera for hereditary angioedema and Lilly's Inluriyo for certain cancer types. These endorsements reflect the growing pipeline of treatments addressing both rare genetic disorders and widespread diseases.Merck & Co.'s acquisition of Cidara Therapeutics for $9.2 billion underscores a strategic pivot towards bolstering its antiviral portfolio. This deal is particularly significant given Cidara's promising influenza antiviral candidate, initially abandoned by Johnson & Johnson. In an era where infectious diseases pose ever-evolving challenges, Merck's investment in antivirals reflects a commitment to advancing therapeutic solutions in this crucial area.However, drug development's inherent uncertainties were highlighted by Bristol Myers Squibb and Johnson & Johnson's joint anticoagulant venture, which faced termination due to a Phase 3 trial failure. This setback emphasizes the challenges and risks entailed in developing novel therapeutics, particularly within high-stakes areas like cardiovascular health.Leadership changes can significantly impact corporate strategy, as seen with Bavarian Nordic following an unsuccessful private equity takeover attempt. Such shifts can influence investor confidence and reshape strategic directions.Investment trends also paint an optimistic picture for innovation within the sector. European life sciences investor Medicxi's successful raising of €500 million signifies robust financial support for biotech ventures. This influx of capital is vital for propelling early-stage research and development efforts across Europe, fostering breakthroughs in chronic and rare disease treatments.In terms of scientific innovation, advancements in bispecific antibody production through AI/ML-driven molecular design promise higher yields and enhanced quality. These technological innovations could revolutionize complex biologics manufacturing, potentially accelerating timelines and expanding therapeutic possibilities.The regulatory landscape is seeing significant activity as well. Notably, FDA officials introduced a novel pathway aimed at accelerating gene editing therapies' development and approval. By facilitating faster market entry for personalized medicines, this regulatory innovation could pave the way for treatments tailored to individual genetic profiles.Kyowa Kirin's collaboration with Kura Oncology reached a milestone with FDA approval for an oral medication targeting acute myeloidSupport the show
‘Als we de Nijmeegse vierdaagse nog een keer lopen, dan doen we het voor het goede doel. Ik wilde graag een doel kiezen dat ligt bij ons ligt en toen kwam ik bij het migraineonderzoek uit.' ‘Ik ben niet migraine. Ik heb migraine.'‘Zoë is heel goed in het verstoppen, maar ik weet ook dat ze goed kan aangeven wat ze daarin van mij of iemand anders nodig heeft of juist niet. Wat ik daarin kan betekenen is dat ik naar haar kan luisteren wat ze nodig heeft.' ‘Er gaat geen dag voorbij dat ik er niet mee bezig ben. Elke dag ben ik erop voorbereid dat het kan gebeuren. Binnen tien minuten kan het weer omslaan. Stel ik ga met de auto naar het werk. Er is geen garantie dat ik met de auto ook weer terug kan komen.' ‘Zoë kijkt heel goed naar wat wat wel kan!' ‘Het is heel naar om je naaste zo te zien, maar luister naar de persoon zelf. En ga na de aanval in gesprek, want dan kun je het erover hebben. Ga de persoon niet pushen. Laat iemand eerst herstellen.' Zoë liep met haar zus Loren de Nijmeegse vierdaagse om geld op te halen voor migraineonderzoek. Vier keer veertig kilometer omdat ze zelf als van jongs af aan last heeft van migraineaanvallen en hoopt dat er meer over bekend wordt. We vroegen of Zoë haar verhaal ook in de podcast wilde delen. Annemiek reisde naar Nijmegen en Loren sloot bij het gesprek aan. Hoe is het om meerdere dagen per maand last van migraine te hebben? En hoe gaat Zoë daarmee om? Het boek ‘Koppijn' van Gisela is uit! Je kunt het bestellen via lokale boekwinkels, bol.com, of via onze webshop (dan steun je ook nog een onderzoek).Voor mensen zoals Zoë en andere migrainepatiënten halen we geld op, zodat we nog beter onderzoek kunnen doen en migraine beter te voorspellen, voorkomen en behandelen. Lees meer over deze actie en doneer via deze link: ‘Inzicht kan helpen migraine te voorkomen' - Leids Universiteits Fonds.Heb je een vraag voor Gisela die we kunnen bespreken in de vragenrubriek? Laat het ons weten via Instagram, LinkedIn of e-mail. De Hoofdpijn podcast is een podcast van het Leidse Hoofdpijn Centrum. Aan het woord: Zoë en Loren PosthumusPresentatie en inhoudelijke montage: Annemiek Lely.Eindmontage en mixage: popuppodcast.studio.Kijk voor meer informatie op www.hoofdpijnonderzoek.nlHet vierde seizoen van de Hoofdpijn podcast wordt mede mogelijk gemaakt door: Pfizer, Organon, Abbvie & Teva.
Recomendados de la semana en iVoox.com Semana del 5 al 11 de julio del 2021
La Prof. María Trinidad Herreros, miembro de la Real Academia Nacional de Medicina, presenta la Alianza Carmen, formada por empresas e instituciones e impulsada por Organon, junto a Nutricia, Medtronic y Ogilvy, para conseguir que haya una equidad de género en los temas de salud.
In this special two-part feature, we welcome Jeremy Sherr, world-renowned homeopath, teacher, and founder of the Dynamis School for Advanced Homeopathic Studies, to share reflections on his 45-year journey in homeopathy and his vision for its evolving future. Jeremy explores the deep relationship between nature, evolution, and healing, offering rare insight into what it means to be truly present in practice. Together with hosts Atiq and Naila, he reflects on:
In this episode of Legal Leaders Exchange, host Jennifer McIver is joined by Catrine Chevalier, Legal Operations specialist at DHL, and Stacy Lettie, Chief of Staff at Organon.This candid conversation explores how lean legal ops teams can deliver outsized impact, even without big budgets or expansive headcount. From auditing invoices with precision to transforming repetitive tasks into opportunities for innovation, Stacy and Catrine share how focus, curiosity, and a strategic mindset can drive real results. Whether you're supporting multiple global business units or juggling competing priorities with limited resources, this episode offers practical insights, relatable stories, and a fresh perspective on what it means to lead legal ops with intention.
There may be a potential long-term shift in global investment flows-- driven by a combination of a weaker dollar and cooling global inflation. Today's Stocks & Topics: Elastic N.V. (ESTC), Market Wrap, Power Solutions International, Inc. (PSIX), Sprott Gold Equity Investor (SGDLX), Pfizer Inc. (PFE), Organon & Co. (OGN), Emerging Markets are Finally Rallying, CommScope Holding Company, Inc. (COMM), How to Navigate the Market, Americold Realty Trust, Inc. (COLD), Eastman Chemical Company (EMN).Our Sponsors:* Check out Anthropic: https://claude.ai/INVEST* Check out Gusto: https://gusto.com/investtalk* Check out TruDiagnostic and use my code INVEST for a great deal: https://www.trudiagnostic.comAdvertising Inquiries: https://redcircle.com/brands
In this rich and eye-opening episode, we sit down with Ewald Stöteler, a veteran homeopath from the Netherlands and author of Hahnemann's Homeopathy, to explore what it truly means to practice in alignment with Hahnemann's original vision. Ewald takes us deep into the often-misunderstood world of miasms, challenging the common notion that prescribing the "right remedy" is enough. With clarity and conviction, he shares why understanding a patient's inherited tendencies and historical disease context is key to unlocking real healing. His passion for homeopathy sparked in the late 1970s and shines through as he explains the importance of reconnecting with the foundational texts and applying them with precision. If you've ever wondered why some remedies don't work the way you expect, this conversation will shift your entire approach. Episode Highlights: 04:04 - Ewald's Journey into Homeopathy 09:38 - Explanation of miasms and disease tendencies 16:27 - Development of LM potencies 19:45 - Using multiple remedies and potencies 22:29 - Overview of Ewald's book "Hahnemann's Homeopathy" 25:58 - Using intercurrent remedies and nosodes 27:36 - Relevance of Hahnemann's methods today 31:16 - Complementary remedies and contextual Materia Medica 35:10 - Three-way approach to prescribing 38:21 - Prescribing multiple remedies in alternation 42:14 - Ewald's teaching and education programs 45:28 - E-learning courses on Hahnemann's homeopathy About my Guests: Ewald Stöteler is a respected Dutch classical homeopath, author, and international educator known for his deep commitment to the original teachings of Dr. Samuel Hahnemann. Born in 1957 and originally trained as a nurse, Stöteler turned to homeopathy in the late 1970s, inspired by personal experiences in oncology care and a desire to find more holistic healing approaches. Over the past four decades, he has dedicated his career to studying and applying Hahnemann's Organon of Medicine and Chronic Diseases, with particular emphasis on LM potencies, miasms, and precise posology. He is the author of the acclaimed book Hahnemann's Homeopathy, which offers a detailed guide to understanding and implementing Hahnemann's full therapeutic model. Stöteler is known internationally for his clear, structured teaching and his ability to bridge theory with clinical practice. He has taught extensively in Europe, Japan, and beyond, emphasizing what he calls the "Contextual Materia Medica" and disease classification based on Hahnemann's original frameworks. As the founder of the Samuel Hahnemann Foundation, he continues to train practitioners in what he views as the purest form of classical homeopathy. His work has significantly influenced a new generation of homeopaths seeking to return to the roots of the discipline while applying it effectively in modern clinical settings. Find out more about Ewald Website:https://ewaldstoteler.com/ If you would like to support the Homeopathy Hangout Podcast, please consider making a donation by visiting www.EugenieKruger.com and click the DONATE button at the top of the site. Every donation about $10 will receive a shout-out on a future episode. Join my Homeopathy Hangout Podcast Facebook community here: https://www.facebook.com/groups/HelloHomies Follow me on Instagram https://www.instagram.com/eugeniekrugerhomeopathy/ Here is the link to my free 30-minute Homeopathy@Home online course: https://www.youtube.com/watch?v=vqBUpxO4pZQ&t=438s Upon completion of the course - and if you live in Australia - you can join my Facebook group for free acute advice (you'll need to answer a couple of questions about the course upon request to join): www.facebook.com/groups/eughom
In this podcast episode, Miguel Regueiro, MD, discusses developing the medical home model for patients with IBD, technological advances for patients in GI and more. • Intro :58 • The interview/about Regueiro 1:03 • Tell us about your family and where you grew up. 1:24 • How did you get interested in medicine? 2:16 • Who were your early influences? 4:18 • What is the medical home? 5:57 • How did you develop the idea to apply the medical home model to IBD? 7:45 • Did you get any funding from the payers for this model to keep costs under control for this patient population? 10:57 • Why hasn't this model become standard of care for patients with complex IBD? 14:13 • What has worked, and what hasn't worked when it comes to adopting an integrative care medical home model? 18:15 • Are there themes patients share as to why they wouldn't want to be enrolled in a medical home? 21:28 • What motivated your change to go from UPMC to become the GI Chief of Cleveland Clinic? 23:09 • What have you learned in this position at Cleveland Clinic? 25:23 • Are you spending a lot of time on the business side of care as opposed to the patient side? 26:34 • How would you recommend that people prepare for having a position like this? 27:34 • Are you seeing a shift in excitement over taking on leadership roles outside of traditional academics? 30:02 • With our clinical tool chest changing so rapidly, is there a common theme that you use to guide the strategy of the institute on what to invest in? 35:06 • What are the challenges that you still see in the ways we are using telehealth? 39:05 • What are some of the most exciting things you see on the horizon in the realm of IBD management? 40:26 • Thank you, Miguel 42:55 • Thanks for listening 45:11 Miguel Regueiro, MD, is the chief of the Digestive Disease Institute at Cleveland Clinic, and professor in the department of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from Regueiro, follow @MRegueiroMD on X. Disclosures: Berry and Chey report no relevant financial disclosures. Regueiro reports being on the advisory boards of and consulting for Abavax, Abbvie, Amgen, Biocon, BMS, Boehringer Ingelheim Pharmaceuticals Inc. (BIPI), Celgene, Celltrion, Gilead, Genentech, Johnson and Johnson, Lilly, Merck, Organon, Pfizer, Prometheus, Roche, Salix, Sanofi, Takeda and UBC.
Significato e caratteristiche dei due scritti aristotelici, la Logica e la Fisica. In cosa consiste la logica di Aristotele, i concetti, le proposizioni e il sillogismo. La concezione della fisica e l'universo aristotelico.
In this heartwarming and insightful episode of the Homeopathy 247 podcast, host Mary Greensmith welcomes Alexandra Ross, a homeopathy student living in rural West Cork, Ireland. Alexandra shares her personal journey into the world of homeopathy, starting with her experiences on her organic dairy farm and how her curiosity about animal health led her to a transformative path of study. From Cows to Clinics: Alexandra's Introduction to Homeopathy Alexandra's journey into homeopathy began not with people—but with cows. Living on a farm with her husband, she encountered situations where conventional veterinary approaches weren't effective. Through research and recommendations, she stumbled upon homeopathy for livestock and enrolled in a course in Germany. Her skepticism vanished the moment a cow in distress delivered a calf “like a bullet” after being given the remedy Caulophyllum. Encouraged by this experience and supported by a homeopathic vet, Alexandra's interest deepened. When her trusted vet retired, she realized she needed to learn more—not just for the animals but also for her family. Choosing the Path of Study Alexandra signed up for a home prescriber course at the Irish School of Homeopathy, which quickly turned into a full four-year commitment. What started as a practical step for supporting her children's health became a deeply transformative life experience. She describes the decision to study homeopathy as both a financial and emotional investment. Travelling to Dublin for in-person classes required planning and expense, but Alexandra values the energy and connection of being physically present with classmates and teachers. A Breakdown of the Four-Year Course Year 1: Students dive into the foundational remedies (polycrests) and philosophy. The Organon by Hahnemann serves as a guiding text. Assignments vary from essays to creative projects like drawings and poems. Year 2: Focus shifts to chronic care and miasms (inherited patterns of illness). Students begin working on real case studies and learn to analyze and prescribe based on deeper themes. Year 3: Students begin their supervised clinical work—seeing real clients while being guided by experienced mentors. Homework now comes from actual case documentation and consultation. Year 4: A continuation of the clinical journey with more responsibility and deeper integration of previous learning. Students participate in school-run clinics and are supported through one-on-one supervision. The Inner Transformation Beyond textbooks and remedies, Alexandra emphasizes how studying homeopathy changes your inner world. Emotional shifts, personal healing, and unexpected breakthroughs are common. Grief she had long suppressed surfaced during her studies, and through support from the school and her own homeopath, she began to truly heal. Alexandra says the friendships formed during the course are powerful and lasting—because everyone is growing, learning, and supporting each other in a shared journey. Advice for Those Considering the Course Her biggest advice? “If you're even a little bit interested, just try the first year.” Many students only take the foundation year and still walk away with a life-changing understanding of health and healing—even if they don't pursue a full license. Visit The Irish School of Homeopathy website here: https://ish.ie/ Subscribe to our YouTube channel and be updated with our latest episodes. You can also subscribe to our podcast channels available on your favourite podcast listening app below: Apple Podcast: https://podcasts.apple.com/us/podcast/homeopathy247-podcast/id1628767810 Spotify: https://open.spotify.com/show/39rjXAReQ33hGceW1E50dk Follow us on our social media accounts: Facebook: https://www.facebook.com/homeopathy247 Instagram: https://www.instagram.com/homeopathy247 You can also visit our website at https://homeopathy247.com/
CX Goalkeeper - Customer Experience, Business Transformation & Leadership
This episode is a powerful conversation with Peter Nicholson about transforming home healthcare through Ohana. Discover how his personal mission and professional background are creating real change in aged care, training caregivers with purpose, and helping older adults live with dignity.About the GuestPeter Nicholson is Managing Director of ALTKEA, a global healthcare consultancy.For five years, he was responsible for the global business development function of Dermavant Sciences GmbH and was GM of its Swiss affiliate before the company was acquired by Organon. Prior to that, he was responsible for the global strategy and business development functions at Galderma (Nestlé / L'Oréal), and before that at Mentor (Johnson & Johnson) and Inamed (Allergan), where he led the groups responsible for strategic partnerships, licensing agreements, acquisitions, joint ventures, divestitures and out-licensing. He spent six years at Amgen working in product development, investor relations and product licensing roles created the company's corporate venture capital program.He became aware of issues in elder care through his parents' health decline and co-founded of OHANA HEALTH, a social impact company focused on professionalizing the vocation of caregiving to upskill workers and empower them to provide person-centered care for older adults while lowering the burden on healthcare budgets.Relevant Links:https://www.linkedin.com/in/peter-nicholson-b9b3ab1b7/https://ohana.healthThe Top 3 Key LearningsEmpowering Caregivers Is Essential: Proper training and support for caregivers improve both job satisfaction and patient outcomes.Technology and AI Can Elevate Aged Care: Personalized learning paths and care planning tools help caregivers and healthcare systems work more effectively.Aging with Dignity Is a Human Right: By rethinking aged care, society can provide more respectful, informed, and compassionate support for the elderly.Chapters00:00 Introduction and Guest Welcome01:22 Guest Introduction: Peter Nicholson's Background03:09 Values Driving Professional Life04:16 The Origin and Meaning of Ohana05:05 Challenges in Aged Care and Demographic Shifts07:18 Inspiration Behind Ohana and Its Mission11:55 Innovative Training and Workforce Development23:21 Future Vision and Global Expansion27:26 Conclusion and Final ThoughtsFollow & Subscribe to the CX Goalkeeper Podcast: - Apple Podcast: http://cxgoalkeeper.com/apple- Spotify: http://cxgoalkeeper.com/spotifyWe'd love to hear your thoughts — leave a comment or share your feedback!
In this eye-opening episode of Hikmat Wehbi Podcast, sponsored by Organon for the Missdiagnosed campaign, Dr. Omar Hallak tells us all about the #1 killer of women, heart disease. Due to differences in symptoms between men and women, as well as the lack of research on women's heart disease, we're witnessing many cases of fatal misdiagnosis, which is why Dr. Omar enlightens us in this podcast about heart attack symptoms in women and the preventative measures that can be taken, as he calls out the medical field for its lack of focus in this field.EDA Notification Code: ONA3676-26052025Invalidation Date: 18/05/2026#hikmatwehbipodcast #podcast#Organon#Hereforherhealth#arabicpodcast#hikmatwehbipodcast #wstudiodxbحكمت_وهبي#حكمت_وهبي_بودكاست#
VERSONO Medical Ltd is delighted to announce that it has been named Dragons' Den winner of the CX Innovation Prize at the international CX Symposium in London last week. The competition was between nine companies from the US, Germany, Israel, Singapore and Ireland, all of which have developed innovative technologies in the field of vascular and endovascular treatment. The US/Galway-based firm faced off in a Dragons' Den-style event in which VERSONO Medical CEO Finbar Dolan presented on the company's plans for its revolutionary FastWire Technology Platform, including its progress on enabling the endovascular treatment of chronic complex total occlusions (CTOs), and the latest developments in its FREEFLOW pivotal study. VERSONO was judged the winner by a panel of Dragons including Robert Mitchell, General Manager of global healthcare company Organon; Prof. Frans Moll, vascular surgeon; Prof. Tilo Kolbel, Director of the German Aortic Centre in Hamburg; Jeffrey B. Jump, founder of Casper-Medical; and Charles Taylor, CEO of Veryan Medical. The event was chaired by Baron Stephen Greenhalgh. FastWire is a truly disruptive technology designed to quickly access previously untreatable complex blockages in arteries, increasing success rates and reducing risk of amputations via endovascular techniques. It uses a novel proprietary ultrasonic technology developed and patented by the company to cross through severe, complex blockages in patient's arteries, above, and below, the knee with Critical Limb Threatening Ischemia (CLTI). The technology has huge potential application in endovascular procedures. VERSONO Medical is in the process of completing the FREEFLOW pivotal study for its FastWire System. Designed to evaluate the safety and effectiveness of the FastWire device through the FDA-approved Investigational Device Exemption (IDE) study, FREEFLOW is being performed in three centres the Vascular Institute of the Midwest (VIM) in Davenport, Iowa; the Cardiovascular Institute of the South (CIS) in Houma, Louisiana; and the Vascular Institute of Chattanooga (VIC) in Tennessee. Subject to the successful completion of the study, the company will seek US market approval to launch FastWire. The Charing Cross (CX) Symposium took place from April 23-25th at the ExcCeL in London. The event brings together world-leading experts in the treatment of vascular and endovascular disease to discuss the challenges and emerging trends in the field. Hosted every three years, the CX Symposium is a prestige event which holds education, innovation and evidence as core values. VERSONO CEO Finbar Dolan says: "It's an honour to win the Dragons Den innovation prize at the CX Symposium in London. This is one of the prestige events in the field of vascular and endovascular treatment and we are thrilled to be selected as the standout candidates in a highly competitive group of companies developing innovative technologies." See more stories here. More about Irish Tech News Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantastic previous episodes and subscribe using whatever platform you like via our Anchor.fm page here: https://anchor.fm/irish-tech-news If you'd like to be featured in an upcoming Podcast email us at Simon@IrishTechNews.ie now to discuss. Irish Tech News have a range of services available to help promote your business. Why not drop us a line at Info@IrishTechNews.ie now to find out more about how we can help you reach our audience. You can also find and follow us on Twitter, LinkedIn, Facebook, Instagram, TikTok and Snapchat.
Biopharma's reaction to the forced resignation of venerable CBER director Peter Marks has been swift and furious, with former FDA Commissioner Robert Califf saying on LinkedIn that “the FDA as we've known it is finished.” Analysts, meanwhile, called Marks' exit “arguably biotech investors' greatest fear,” as company shares across the industry tumbled. Marks' announcement added insult to injury for the agency, which was already reeling from the announced cuts of 10,000 employees across the Department of Health and Human Services, including 3,500 FDA staffers. Those layoffs began to roll out on Tuesday as some employees showed up to work only to discover they no longer had a job. Amid all this chaos, Cantor Fitzgerald analysts called for Kennedy himself to get the axe, saying in part that he was “undermining the trusted leadership of health care in this country.” Despite the turmoil, drug development continues in the obesity space, with Novo Nordisk presenting mixed data from its semaglutide franchise at the American College of Cardiology's annual conference last weekend. While an oral version of the blockbuster drug showed cardiovascular benefits for some patients, it failed to change the trajectory of other major adverse cardiovascular events. Meanwhile, Novo continues its battle against compounding pharmacies manufacturing copycat versions of semaglutide—as multiple players scramble for a piece of this massive pie. On the Alzheimer's front, Eli Lilly's Kisunla failed last week to win the recommendation of the EU's Committee for Medicinal Products for Human Use. This decision is consistent with CHMP's recent stance on anti-amyloid antibodies, as Biogen and Eisai have also struggled to get Leqembi approved in Europe. On a positive note, pharma R&D returns grew again in 2024, but Deloitte warned that this progress is “fragile.” The firm urged companies to be bold and embrace cutting edge technology like gene therapy and AI. These returns can't help everyone, however, as the past week has seen an uptick in layoffs across biopharma, including at Carisma Therapeutics, Organon and Tenaya Therapeutics. Finally, as April kicks off cancer conference season, BioSpace took a deep dive into the recent action in the always-hot in radiopharmaceuticals space.
We're not in Kansas anymore. We're in the Jetsons Era. Legal Data Intelligence isn't just tech, it's talent, timing, and the ability to see around corners. In this episode, I sat down with Stacy Lettie, Chief of Staff to the General Counsel at Organon, and we went from Disney to data to dogs with AI collars. Yes, really. We talked: Why the future of legal starts with foundations (Small World → Tron) What makes a great Chief of Staff When imposter syndrome disappears (spoiler: when you earn it) And the moment we decided—live, in-person—to build AI agents at Microsoft this July
Wendy Lund isn't just a powerhouse in healthcare marketing — she's also a longtime family friend, thanks to her working alongside my sister Lisa years ago -- also in healthcare marketing -- then becoming neighbors and "besties." As a result, I also know Wendy is a longtime advocate for women's health, and is as passionate about promoting good information as she is about, well, her dog, Yogi! Yogi And that is one cute dog: spoiler alert in case you miss the video. As Chief Client Officer of Health@WPP, former CEO of GCI Health, and former Chief Communications Officer at Organon, Wendy has been a force in transforming how we talk about — and invest in — women's healthcare. In May 2025 she's being honored with the Pinnacle Award by MM+M for her leadership and impact. The Imperative for Information and Innovation around Women's Health - Health@WPP at SXSW In yet another heartfelt, informative, and often funny conversation apropos Women's History Month, Wendy explains why Health@WPP believes wise innovation, factual and frequent information around women's healthcare is an imperative. Those are the pillars driving that progress — and why that's not just good for society, but great for business.
Support document: https://drive.google.com/file/d/1C7AklutZZ1SeHO-jBDnGv3CUXrBr6Bge/view?usp=drive_link Find out more about Trinity Health Hub at https://trinityhealthhub.com/.
Which edition of the Organon best informs one's choice of potency? Does the idea of choosing a potency make you freeze up a bit? Join us for part 2 of our continuing conversation about aspects of potency and posology that aren't widely discussed. We hope this explanation helps you begin to break through and melt away feelings of anxiety around this topic. https://academyofhomeopathyeducation.com/professional-program/ Denise Straiges MA, CCH, RSHom(NA), PCH is fiercely committed to raising the bar in academic and clinical training for all Homeopaths. She is the President and Clinical Director of The Academy of Homeopathy Education (AHE), and established HOHM Foundation, whose initiatives include the Homeopathy Help Network, a not-for-profit, research-based initiative focused on delivering high quality, affordable Homeopathy care to all. Under her leadership, AHE was named exclusive educational provider for the American Institute of Homeopathy (AIH), the oldest medical society in the US.Denise is a 2023 graduate of Johns Hopkins University School of Medicine. Her dissertation, Contingent Evolution: Homeopathy and 19th Century Biomedicine explores how the uptake of bacteriological discoveries into the canon of 19th century medical knowledge was an interdependent and non-linear process in both orthodox and heterodox spaces. In conjunction with HOHM Foundation, she has published numerous peer-reviewed articles on clinical outcomes and education in integrative medicine, and her dissertation was released as a book in 2023. She is completing a compendium of homeopathic case analysis with expected publication in 2024/25.Denise maintains a busy practice in classical homeopathy with a focus on complex neurological and autoimmune conditions and provides clinical supervision and mentorship to students and professional homeopaths around the world. Alastair Gray has a Ph.D. in Public Health. More specifically he is an expert in the field of Complementary Medicine education. Much of his research has a focus on technologies in the field of CM and learning technologies in the education of future practitioners. He teaches at and heads the academic, operations, and research at the Academy of Homeopathy Education. In addition, he holds various consulting roles: academic (College of Health and Homeopathy, NZ), educational (National Centre for Integrative Medicine, UK), as well as consulting to many organizations on homeopathic provings and e-learning worldwide. A regular seminar and conference presenter worldwide and having spent a decade in the higher education arena in Australia, he is the author of 23 books and numerous articles on primary research in natural medicine. Originally educated as a historian, he teaches the history of health, healing, and medicine at schools, colleges, and universities in multiple countries. Alastair has been in practice for more than 30 years.
Which edition of the Organon of Medicine best informs one's choice of potency? Does the idea of choosing a potency make you freeze up a bit? We hope this explanation helps you begin to melt away feelings of anxiety around this topic. https://academyofhomeopathyeducation.com/professional-program/ Denise Straiges MA, CCH, RSHom(NA), PCH is fiercely committed to raising the bar in academic and clinical training for all Homeopaths. She is the President and Clinical Director of The Academy of Homeopathy Education (AHE), and established HOHM Foundation, whose initiatives include the Homeopathy Help Network, a not-for-profit, research-based initiative focused on delivering high quality, affordable Homeopathy care to all. Under her leadership, AHE was named exclusive educational provider for the American Institute of Homeopathy (AIH), the oldest medical society in the US.Denise is a 2023 graduate of Johns Hopkins University School of Medicine. Her dissertation, Contingent Evolution: Homeopathy and 19th Century Biomedicine explores how the uptake of bacteriological discoveries into the canon of 19th century medical knowledge was an interdependent and non-linear process in both orthodox and heterodox spaces. In conjunction with HOHM Foundation, she has published numerous peer-reviewed articles on clinical outcomes and education in integrative medicine, and her dissertation was released as a book in 2023. She is completing a compendium of homeopathic case analysis with expected publication in 2024/25.Denise maintains a busy practice in classical homeopathy with a focus on complex neurological and autoimmune conditions and provides clinical supervision and mentorship to students and professional homeopaths around the world. Alastair Gray has a Ph.D. in Public Health. More specifically he is an expert in the field of Complementary Medicine education. Much of his research has a focus on technologies in the field of CM and learning technologies in the education of future practitioners. He teaches at and heads the academic, operations, and research at the Academy of Homeopathy Education. In addition, he holds various consulting roles: academic (College of Health and Homeopathy, NZ), educational (National Centre for Integrative Medicine, UK), as well as consulting to many organizations on homeopathic provings and e-learning worldwide. A regular seminar and conference presenter worldwide and having spent a decade in the higher education arena in Australia, he is the author of 23 books and numerous articles on primary research in natural medicine. Originally educated as a historian, he teaches the history of health, healing, and medicine at schools, colleges, and universities in multiple countries. Alastair has been in practice for more than 30 years.
Host: Perry Elliott Guest: Hector Bueno Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1796?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Hector Bueno has declared to have potential conflicts of interest to report: research funding from the European Union (EU4H-2022-JA-03), Instituto de Salud Carlos III, Spain (FORTALECE program, PI21/01572), Sociedad Española de Cardiología, AstraZeneca, Boehringer Ingelheim, Janssen, and Novartis; and has received in the past consulting/speaking fees from Astra-Zeneca, Novartis, Novo Nordisk and Organon. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion.
ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Hypertensive disorders during pregnancy Depression and heart disease Mythbusters: "The French Paradox" Host: Perry Elliott Guests: Carlos Aguiar, Martha Gulati, Hector Bueno Want to watch that episode? Go to: https://esc365.escardio.org/event/1796 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Martha Gulati, Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Hector Bueno has declared to have potential conflicts of interest to report: research funding from the European Union (EU4H-2022-JA-03), Instituto de Salud Carlos III, Spain (FORTALECE program, PI21/01572), Sociedad Española de Cardiología, AstraZeneca, Boehringer Ingelheim, Janssen, and Novartis; and has received in the past consulting/speaking fees from Astra-Zeneca, Novartis, Novo Nordisk and Organon. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
"In the healthy continuum of life..." Jeremy Sherr presents his adaptive translation of Hahnemann's Organon in modern language. We began the episode with Jeremy's enthusiasm for his project to make the Organon more accessible to today's homeopaths. He explained his adaptive translation approach, updating references to address contemporary issues and replacing outdated terms with modern equivalents. We also discussed Jeremy's new book on Krypton, reflecting his long-standing interest in noble gases. He shared intriguing insights about the remedy's links to time and consciousness, highlighting how Krypton represents both perfection and imperfection. Throughout the episode, we explored the philosophical aspects of homeopathy, including the significance of language and the nuances of defining health and disease. Episode Highlights: 01:39 - Updates on the Organon project 05:21 - Defining health often overlooked in allopathic medicine 07:54 - Emphasizing “regulates” over “governs” for harmony in health 09:27 - The importance of language in homeopathy 16:01 - Insights on Krypton and its significance 19:39 - The nature of sleep and time 21:59 - The Importance of Clients Being Open in Consultations 24:22 - Unusual Experiences During Remedy Provings 28:11 - Advocating for Fair Compensation in Homeopathy 43:55 - Discussion on suppression in homeopathy 53:18 - Overcoming fears about prescribing remedies 57:23 - The implications of short homeopathy courses 01:08:28 - Jeremy's resources and upcoming projects About my Guest: Jeremy Sherr is a prominent figure in the field of homeopathy, born in South Africa and raised in Israel. He began his formal studies in 1980 at the College of Homoeopathy in London while also completing a degree in Acupuncture at the International College of Oriental Medicine. Although he practices homeopathy exclusively, his deep understanding of Chinese Medicine enriches his approach. Jeremy founded the Dynamis School in 1986, which is the longest-running post-graduate homeopathy course globally. He has shared his expertise through teaching across multiple countries, including England, Canada, and Japan, and maintains a busy global practice. An accomplished author, Jeremy has published numerous books and articles, including bestsellers like Dynamics and Methodology of Homoeopathic Provings and Dynamic Materia Medica: Syphilis. He has proved over 40 new homeopathic remedies and is actively working on a series of books on noble gases. Additionally, Jeremy co-founded Homeopathy for Health in Africa in 2008, which has expanded to 20 clinics in Tanzania, treating over 7,000 patients. With fellowships from the Society of Homoeopaths, a Ph.D. from Medicina Alternativa, and honorary professorships in China and Argentina, Jeremy Sherr continues to be a leading voice in homeopathy and global health initiatives. Find out more about Jeremy Website: www.dynamis.edu www.homeopathyforhealthinafrica.org Check out Jeremy's Courses https://www.patreon.com/JEREMYSHERR If you would like to support the Homeopathy Hangout Podcast, please consider making a donation by visiting www.EugenieKruger.com and click the DONATE button at the top of the site. Every donation about $10 will receive a shout-out on a future episode. Join my Homeopathy Hangout Podcast Facebook community here: https://www.facebook.com/groups/HelloHomies Follow me on Instagram https://www.instagram.com/eugeniekrugerhomeopathy/ Here is the link to my free 30-minute Homeopathy@Home online course: https://www.youtube.com/watch?v=vqBUpxO4pZQ&t=438s Upon completion of the course - and if you live in Australia - you can join my Facebook group for free acute advice (you'll need to answer a couple of questions about the course upon request to join): www.facebook.com/groups/eughom
Becky Edwards, chief communications officer for Organon, recaps the increased spotlight on gender balance and female athlete needs at this summer's Paris Olympics, as well as how womens' health advocacy can build on that momentum. Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Amazon has partnered with Talkspace to expand its digital health benefits program, which also includes Omada Health. Community Health Systems (CHS) subsidiary is acquiring 10 urgent care centers, following in the footsteps of other for-profit health systems. Steward Health Care auctioned off Glenwood Regional Medical Center for $500,000, but there are concerns about the continued involvement of hospital landlord Medical Properties Trust in operations. The text also includes sponsored content on safeguarding healthcare against ransomware and cybercrime, as well as information on trends in telehealth and strategies for improving provider data accuracy for payers. Healthcare Dive provides news and insights for healthcare leaders and is a publication operated by Industry Dive.Roivant's subsidiary, Dermavant, is being acquired by Organon, giving Organon access to a psoriasis and eczema cream called Vtama. This acquisition will provide Roivant with additional cash to fund its research and development plans. Meanwhile, biotech M&A activity has plateaued, with private company acquisitions continuing while public company acquisitions have slowed down. One biotech, Ratio Therapeutics, backed by Bristol Myers Squibb, is optimistic about the boom in radiopharma and the pharmaceutical industry's shift towards targeted radiation drugs. In other news, Novartis' Kisqali has received expanded FDA approval which could double its market for breast cancer treatment. Additionally, Express Scripts is suing the FTC over a report critical of pharmacy benefit manager business practices. The industry is also exploring new ways to deliver genetic therapies and improve clinical trial execution through systems thinking. Overall, the biopharma industry is experiencing exciting times with various developments and advancements in drug development and healthcare technology.Zimmer has decided to pull its hip implant off the market due to fracture risk, with plans to phase out its use by December. Merit Medical has acquired Cook's lead management business for $210 million, adding devices used in heart rhythm device procedures to its portfolio. Synchron has connected brain-computer interface technology to Amazon Alexa, allowing patients to control various functions without using their hands or voice. Senseonics has received FDA clearance for a one-year continuous glucose monitoring system, and Boston Scientific has closed its acquisition of Silk Road Medical. The wearables market is expected to grow by 13% annually between 2024 and 2030, highlighting the importance of adhesives in wearable device development. AI is increasingly influencing the value chain of medical device companies, and manufacturers are exploring ways to utilize AI throughout the product lifecycle. These developments reflect the ongoing innovation and evolution within the medtech industry.Roivant has sold Dermavant to Organon in a deal worth up to $1.2 billion, allowing Roivant to focus on their autoimmune-focused Immunovant and upcoming trials. Summit Therapeutics' bispecific for non-small cell lung cancer has shown promise against Keytruda but still needs more data. Other news includes the FDA approving Keytruda for pleural mesothelioma, Bernie Sanders claiming generics companies can offer a cheaper alternative to Ozempic, Novartis expanding Kisqali's use in breast cancer, and HRSA threatening sanctions against J&J. In the world of enzyme development, SignalChem Biotech offers tailored services. Additionally, new gene therapies for sickle cell disease are reaching patients, and the race for an obesity pill is heating up among companies like Novo, Roche, and Terns.The FDA is facing challenges with conducting overseas drug manufacturing inspections, with 42% of registered plants overdue for inspections. Indian drugmaker Zydus Lifesciences received a warnin
Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention may impact disease course. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: April Armstrong, MD, MPH has served as a research investigator, scientific advisor, or speaker to AbbVie, Amgen, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Mindera, Nimbus, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Takeda, Organon, Regeneron, Pfizer and Ventyx Lisa Beck MD, consults for Abbvie, Allakos, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Astria Therapeutics, Celldex, Dermavent, DermTech, Escient Pharma, Eli Lilly Company, Evelo Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Numab Therapeutics, Pfizer, Proteologix, Rapt Therapeutics, Regeneron, Ribon Therapeutics, Sanofi/Genzyme, Sanofi-Aventis, Sitryx Therapeutics, Stealth BioTherapeutics, Trevi Therapeutics, Union Therapeutics, Xencor and Yuhan and has been an Investigator for Abbvie, Astra-Zeneca, DermTech, Kiniksa, Pfizer, Regeneron, Ribon Therapeutics and Sanofi. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2401395 - 1.0 - 07/2024 MAT-US-2407636 v1.0 - P Exp Date: 07/31/2026
The Homeopathy Health Show welcomes Dr. Christina Chambreau to the show to talk about her work as a Homeopathic Veterinarian, author and teacher. Dr. Chambreau is an internationally known homeopathic veterinarian, lecturer and author. She graduated from the University of Georgia Veterinary College in 1980. Several years later a client told her about homeopathy and a local veterinarian sent her bottles of Cantharis and Urtica from the Washington Pharmacy for “bladder problems.” Months later a cat with cystitis came into the practice and was able to stop taking antibiotics for the first time in 3 years after taking one or both of “this stuff that might help your cat”. Very interested, Christina attended a class at the National Center for Homeopathy Summer School taught by George MacLeod and began using homeopathy in her veterinary practice. Her successes (those initial miracles that keep us studying homeopathy) encouraged her to take a second class the next year with Dr. MacLeod and began Dr. Paul Herscu's yearlong training program. By then, Dr. Pitcairn was offering annual weekend classes on homeopathy for animals which she religiously attended. Since 1988 she has used primarily homeopathy in her practice and began teaching. She is a co-founder of the Academy Of Veterinary Homeopathy, was on the faculty of the National Center for Homeopathy Summer School teaching repertory and animal classes, was an adjunct faculty at the Maryland Veterinary Technician Program and is on the faculty of the Holistic Actions for animal health which is based on homeopathic principles. She teaches courses on homeopathy and holistic health virtually and around the world to lay and veterinary students. Her commitment is to de-mystify homeopathy, to show how healing of all types follows the principles of the Organon and to have people realize the power (for good and bad) of remedies, and how this approach helps our environment. Using the principles of homeopathy, she shows how to experiment with the myriad healing modalities available and evaluate their results properly. Writing the Healthy Animal's Journal (and now the dog and cat ebooks, soon the horse journal, too) was needed so people could easily track the symptoms and essence of their animals to be able to evaluate the direction of response to any treatments. She is very practical and eschews “Do this because it worked for me…” suggestions, rather teaches the underlying principles whenever possible. She also wrote the kindle book – Fleas Be Gone: A holistic veterinarians guide to natural flea control. She is co-author of the Homeopathic Repertory: A Tutorial (Karen Allen) and How To Have A Stress Free Wedding (Mort Orman). Be inspired and join the conversation. The ‘VOICE OF HOMEOPATHY' on radio and podcast. Support Homeopathy on Radio & Podcast by subscribing to the Homeopathy Health Show.
In this week's episode, Donnie Wooten, PharmD, Head of Global Field Medical Excellence at Organon and Kelly Lo, Global Field Medical Excellence at Amgen discuss the Demystifying and Unpacking of Omnichannel engagement. Learn more about…
Dr Yashika Arora is a young, dynamic homeopath, organiser of webinars, regular CME's & Seminars in Delhi & all over India with various Homoeopathic associations. She can be contacted at doctoryashikaarora@gmail.com She is an Alumni of NHMC, Delhi, is currently pursuing MD (Hom) from DKMMHMC Aurangabad. Achiever of STSH 2015-16 Scholarship Programme, organised by C.C.R.H., Delhi, Titled “Efficacy of Homoeopathic medicines in the Treatment of Alopecia Areata”, for a period of 6 months under C.C.R.H (2015-16). A speaker at various platforms and took various webinars recently with Aurangabad & Latur Group, Homoeopathic Development Association, AIHSAYA, IHMA, Kavitha Holistic Approach, Bhargava Phytolab, Homeopathy 360, Homeopathy Junction & ASHA Homeopathic Academy. Speaker on “One Sided Diseases” in National Homoeopathic Conference, organized on January 7th, 2018. Paper Presentation at 21st All India Congress by H.M.A.I at Patna on 24th & 25th November, 2018 on the topic, "Utility of Dulcamara in Warts – A Non-Controlled Experimental Study". Speaker at C.M.E. organized by D.H.M.A., on the topic, "The Magnanimit-ic Personality of Kali group" on 30th December, 2018 at Delhi Public library. Speaker on “Aurum Group” in a C.M.E. organized on April 21, 2019 by H.H.M.R. Association at NHMC & H, Delhi. Speaker on the topic “Homoeopathic aetiology of Autoimmune disorders on 2nd June, 2019 at Dr. B.R. Sur Homoeopathic Medical College and Hospital, Delhi She has written many articles for the magazines and journals like NewLife Era, DARE, The Homoeopathic Heritage, Homeomiracle, DUM SPIRO SPERO E-Journal, Deepshika, Homoeopathic Journal (online), Homoeopathy LInks (online), Homeopathic Pulse, Homeoplus, Homeodrugshots (online), Nhmc magazine, Vital informer, Homoeo Tarang, Hahnemann ki Awaz, AIHSAYA Journal, Gems of Homoeopathy, Homeopathy 360, Homeoreader, Sukul Homoeopathy, Homeoadda & DARE Facebook page, Blog writer at She & Her trust website. She is also an achiever of the essay writing competition organised by IIHP in 2015 and 2018 . Certificate of excellence by Dr Lal Singh Foundation Winner of essay competition by H.M.A.I. on “Relevance of Organon in Homoeopathic Practice”. (March, 2019) Winner of National Essay Competition organised by Bach Flower Therapy and Teaching - India on the topic "Disease is nothing but disharmony between mind and soul 20th November, 2019. She has got the appreciation award by Board of homeopathic system of medicine Delhi in 2018 She won the Homeopathic icon award by Delhi Homeopathic Federation in 2019 and also got Chikitsa Seva Ratna award by Bhartiya homeopathic panel. Young Homoeopath Oration Award by South Delhi Homoeopathic Association in Kent's Memorial Lectures on 14th & 15th September, 2019. 3rd Prize in CCRH Film/Video Making Competition (2020) Presented Poster on World Homoeopathy day in National Convention, 10th April, 2018, organised by C.C.R.H. & AYUSH. Volunteer at Perfect Health Mela for 2 years. She is a contributing author of Textbook of Obstetrics and neonatology with Homoeopathic Therapeutics by Dr Trupti Bhamre Editor of The Golden Thread of Homoeopathic Medicine book by Dr Dilip Soni. Chief Editor of the Book, Homeopathy Through Harmony and Totality, by Dr Ajit Kulkarni Editor of the book, Cracking the Homeopathic Codes of Breast Cancer, by Dr Sunirmal Sarkar & Dr Shruti Shah Editor of Vaccine Injured children by Dr Isaac Golden. Other Contributions: Editor of The Homoeopathic Heritage (a peer-reviewed journal) & Homeopathy 360. Organising secretary of DREAMS Innovative Homoeopaths. National General Secretary (Students Cell) of All India Homeopathic Students & Youth Association. AD's Controller in DARE Journal Former Chief Editor of Journal – “Homoeomiracle” and Online Journal – “DUM SPIRO SPERO” (Dr. Bindra's cancer Homoeopathic healing centre). Former President, Homoeopathic Medical Association, Delhi, 2017-18. If you would like to support the Homeopathy Hangout Podcast, please consider making a donation by visiting www.EugenieKruger.com and click the DONATE button at the top of the site. Every donation about $10 will receive a shout-out on a future episode.
The Homeopathy Health Show welcomes Homeopath, Author and Teacher, Dr. Manish Bhatia to the show. Dr. Bhatia is the founder of the online platform hpathy.com, a leading online Homeopathy portal providing resources on Homeopathy, in the form of articles, research papers, and case-reviews. This online portal boasts an impressive ½ million visitors each month. Dr. Bhatia talks about his background as a computer software programmer, what led him to Homeopathy, and how we founded hpathy.com, and how he subsequently established the Asha Homeopathy center, one of the leading classical Homeopathy centers in India today. We also talk about the marvellous 3-volume work that he has authored, Lectures on Organon of Medicine, and why it is so needed for modern times. Dr. Bhatia also shares his insights into how one can practice Homeopathy without getting overwhelmed by the many systems that exist, and how best to get a firm footing, and grounding, in the basic principles of Homeopathy. Be inspired and join the conversation. The ‘VOICE OF HOMEOPATHY' on radio and podcast. Support Homeopathy on Radio & Podcast by subscribing to the Homeopathy Health Show.
Dr. Charlotte Owens is sharing with Jackie the societal inequities she witnessed firsthand and how they have shaped her commitment to making a difference. From understanding real-life factors that impact health to the disparities in maternal health outcomes, the Senior Vice President and Head of Global Medical Affairs and Outcomes Research at Organon emphasizes the need for a more inclusive healthcare system that empowers women to advocate for their well-being. Tune in to hear what Dr. Owens and Organon are doing to address systemic biases in healthcare, learn actionable steps for advocating for your health, and understand the importance of speaking up, asking questions, and seeking support. "Diversity Beyond the Checkbox" is presented by The Diversity Movement and hosted by Inc 200 Female Founders award winner, Jackie Ferguson. Check out exclusive bonus content on BeyondtheCheckbox.com! This show is proud to be a part of The Living Corporate Network and to be produced by Earfluence.
In this episode, I divide losartan and Cozaar into syllables, tell you which syllables to emphasize, and share my sources. The written pronunciations can be helpful, so you can see them below and in the show notes on thepharmacistsvoice.com. The purpose of my pronunciation episodes is to provide the intended pronunciations of drug names from reliable sources so you feel more confident saying them and less frustrated learning them. Losartan = loe-SAR-tan, emphasize SAR (source: USP Dictionary Online) Cozaar = CO-zar, emphasize CO (patient information on Organon's website) If you know someone who needs to learn how to say losartan and Cozaar, please share this episode with them. Subscribe to/follow this podcast for all future episodes. Thank you for listening to episode 272 of The Pharmacist's Voice ® Podcast! To read the FULL show notes, visit https://www.thepharmacistsvoice.com. Click the Podcast tab, and select episode 272. Subscribe to or follow The Pharmacist's Voice ® Podcast to get each new episode delivered to your podcast player and YouTube every time a new one comes out! Apple Podcasts https://apple.co/42yqXOG Spotify https://spoti.fi/3qAk3uY Amazon/Audible https://adbl.co/43tM45P YouTube https://bit.ly/43Rnrjt Links from this episode USP Dictionary Online (aka “USAN”) **Subscription-based resource USP Dictionary's (USAN) pronunciation guide (Free resource on the American Medical Association's website) Patient Information for Cozaar ® via Organon's website accessed April 1, 2024 The Pharmacist's Voice Podcast Episode 269, pronunciation series episode 28 (tirzepatide) The Pharmacist's Voice Podcast Episode 267, pronunciation series episode 27 (atorvastatin) The Pharmacist's Voice Podcast Episode 265, pronunciation series episode 26 (omeprazole) The Pharmacist's Voice Podcast Episode 263, pronunciation series episode 25 (PDE-5 inhibitors) The Pharmacist's Voice Podcast Episode 259, pronunciation series episode 24 (ketorolac) The Pharmacist's Voice ® Podcast episode 254, pronunciation series episode 23 (Paxlovid) The Pharmacist's Voice ® Podcast episode 250, pronunciation series episode 22 (metformin/Glucophage) The Pharmacist's Voice Podcast ® episode 245, pronunciation series episode 21 (naltrexone/Vivitrol) The Pharmacist's Voice ® Podcast episode 240, pronunciation series episode 20 (levalbuterol) The Pharmacist's Voice ® Podcast episode 236, pronunciation series episode 19 (phentermine) The Pharmacist's Voice ® Podcast episode 228, pronunciation series episode 18 (ezetimibe) The Pharmacist's Voice ® Podcast episode 219, pronunciation series episode 17 (semaglutide) The Pharmacist's Voice ® Podcast episode 215, pronunciation series episode 16 (mifepristone and misoprostol) The Pharmacist's Voice ® Podcast episode 211, pronunciation series episode 15 (Humira®) The Pharmacist's Voice ® Podcast episode 202, pronunciation series episode 14 (SMZ-TMP) The Pharmacist's Voice ® Podcast episode 198, pronunciation series episode 13 (carisoprodol) The Pharmacist's Voice ® Podcast episode 194, pronunciation series episode 12 (tianeptine) The Pharmacist's Voice ® Podcast episode 188, pronunciation series episode 11 (insulin icodec) The Pharmacist's Voice ® Podcast episode 184, pronunciation series episode 10 (phenytoin and isotretinoin) The Pharmacist's Voice ® Podcast episode 180, pronunciation series episode 9 Apretude® (cabotegravir) The Pharmacist's Voice ® Podcast episode 177, pronunciation series episode 8 (metoprolol) The Pharmacist's Voice ® Podcast episode 164, pronunciation series episode 7 (levetiracetam) The Pharmacist's Voice ® Podcast episode 159, pronunciation series episode 6 (talimogene laherparepvec or T-VEC) The Pharmacist's Voice ® Podcast episode 155, pronunciation series episode 5 Trulicity® (dulaglutide) The Pharmacist's Voice ® Podcast episode 148, pronunciation series episode 4 Besponsa® (inotuzumab ozogamicin) The Pharmacist's Voice ® Podcast episode 142, pronunciation series episode 3 Zolmitriptan and Zokinvy The Pharmacist's Voice ® Podcast episode 138, pronunciation series episode 2 Molnupiravir and Taltz The Pharmacist's Voice ® Podcast episode 134, pronunciation series episode 1 Eszopiclone and Qulipta
When was the last time you asked yourself if your career is truly headed where you want to go? Do you feel like you're just coasting along or following someone else's script? It's tempting but playing it safe is no way to build a career that allows you to grow into your best self. In today's conversation, Grace helps you grab the wheel and chart a course aligned with your true aspirations. We'll explore how to move past the myth of “work-life balance” and integrate your personal and professional lives in an intentional way. Grace shares how to define your unique “cardinal direction,” take control of your career GPS, and build “professional equity” as you move ahead. She also reveals how to course-correct when you veer off track so you can leave a legacy you're proud of. SPARKED HOT TAKE WITH: Grace Puma | Book Grace Puma is the former executive vice president and COO of PepsiCo, and before that held senior positions with United Airlines, Kraft Foods, Motorola, and Gillette. A board member of both Organon & Co and Target, she has been ranked on the “Most Powerful Latina” list by Fortune magazine and recognized as the “Executive of the Year” by Latina Style magazine. Puma holds a BA in business administration and economics from Illinois Benedictine University. She lives in Tampa, Florida. HOSTED BY: Jonathan Fields Jonathan is a dad, husband, award-winning author, multi-time founder, executive producer and host of the Good Life Project podcast, and co-host of SPARKED, too! He's also the creator of an unusual tool that's helped more than 650,000 people discover what kind of work makes them come alive - the Sparketype® Assessment, and author of the bestselling book, SPARKED. How to submit your question for the SPARKED Braintrust: Wisdom-seeker submissions More on Sparketypes at: Discover Your Sparketype | The Book | The Website Find a Certified Sparketype Advisor: CSA Directory Coaches & Leaders: Tap a Game-Changing Credential - The Certified Sparketype® Advisor Training. This powerful training and certification is designed to help you: Deliver more outstanding service while helping your clients and/or team members live a more-fulfilling life, and craft a more purpose-led, meaningful, and alive career path. Better understand how to powerfully motivate and inspire employees or teams to perform at the highest levels, so that they generate exceptional results and do more of what makes them come alive. AND… get there much faster with next-gen tools that do what no others can. Learn more HERE. Next Training starts March 2024 Presented by LinkedIn.
This episode first premiered in 2022, for members of
© 2020-2026 Ivy Podcast Discovery LLC
